Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1963 1
1964 1
1965 1
1966 1
1970 2
1972 1
1974 2
1975 2
1977 1
1978 2
1979 2
1980 2
1981 1
1982 2
1983 1
1987 2
1988 2
1992 1
1993 1
1994 1
1995 2
1996 2
1999 4
2000 1
2001 1
2003 2
2004 1
2007 1
2008 2
2013 2
2014 3
2015 5
2016 4
2017 4
2018 2
2019 1
2020 3
2021 2
2022 5
2023 4
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for simmons jl[au]
Your search for Sammons JL[au] retrieved no results
Heterogeneity in Melanoma.
Ng MF, Simmons JL, Boyle GM. Ng MF, et al. Among authors: simmons jl. Cancers (Basel). 2022 Jun 20;14(12):3030. doi: 10.3390/cancers14123030. Cancers (Basel). 2022. PMID: 35740696 Free PMC article. Review.
Topical treatments for skin cancer.
Cullen JK, Simmons JL, Parsons PG, Boyle GM. Cullen JK, et al. Among authors: simmons jl. Adv Drug Deliv Rev. 2020 Jan 1;153:54-64. doi: 10.1016/j.addr.2019.11.002. Epub 2019 Nov 6. Adv Drug Deliv Rev. 2020. PMID: 31705912
BRN2 expression increases anoikis resistance in melanoma.
Pierce CJ, Simmons JL, Broit N, Karunarathne D, Ng MF, Boyle GM. Pierce CJ, et al. Among authors: simmons jl. Oncogenesis. 2020 Jul 6;9(7):64. doi: 10.1038/s41389-020-00247-1. Oncogenesis. 2020. PMID: 32632141 Free PMC article.
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.
Cullen JK, Yap PY, Ferguson B, Bruce ZC, Koyama M, Handoko H, Hendrawan K, Simmons JL, Brooks KM, Johns J, Wilson ES, de Souza MMA, Broit N, Stewart P, Shelley D, McMahon T, Ogbourne SM, Nguyen TH, Lim YC, Pagani A, Appendino G, Gordon VA, Reddell PW, Boyle GM, Parsons PG. Cullen JK, et al. Among authors: simmons jl. J Immunother Cancer. 2024 Apr 24;12(4):e006602. doi: 10.1136/jitc-2022-006602. J Immunother Cancer. 2024. PMID: 38658031 Free PMC article.
Phencyclidine-associated acute rhabdomyolysis.
Cogen FC, Rigg G, Simmons JL, Domino EF. Cogen FC, et al. Among authors: simmons jl. Ann Intern Med. 1978 Feb;88(2):210-2. doi: 10.7326/0003-4819-88-2-210. Ann Intern Med. 1978. PMID: 626451
Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.
Cullen JK, Boyle GM, Yap PY, Elmlinger S, Simmons JL, Broit N, Johns J, Ferguson B, Maslovskaya LA, Savchenko AI, Mirzayans PM, Porzelle A, Bernhardt PV, Gordon VA, Reddell PW, Pagani A, Appendino G, Parsons PG, Williams CM. Cullen JK, et al. Among authors: simmons jl. Sci Rep. 2021 Jan 8;11(1):207. doi: 10.1038/s41598-020-80397-9. Sci Rep. 2021. PMID: 33420238 Free PMC article.
73 results